- Home
- PBT vs TYRA Comparison
PBT vs TYRA Comparison
Compare PBT & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- TYRA
- Stock Information
- Founded
- PBT 1980
- TYRA 2018
- Country
- PBT United States
- TYRA United States
- Employees
- PBT N/A
- TYRA N/A
- Industry
- PBT Oil & Gas Production
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- PBT Energy
- TYRA Health Care
- Exchange
- PBT Nasdaq
- TYRA Nasdaq
- Market Cap
- PBT 838.5M
- TYRA 681.7M
- IPO Year
- PBT N/A
- TYRA 2021
- Fundamental
- Price
- PBT $18.43
- TYRA $14.16
- Analyst Decision
- PBT
- TYRA Strong Buy
- Analyst Count
- PBT 0
- TYRA 7
- Target Price
- PBT N/A
- TYRA $30.71
- AVG Volume (30 Days)
- PBT 118.7K
- TYRA 197.7K
- Earning Date
- PBT 01-01-0001
- TYRA 11-14-2025
- Dividend Yield
- PBT 1.77%
- TYRA N/A
- EPS Growth
- PBT N/A
- TYRA N/A
- EPS
- PBT 0.35
- TYRA N/A
- Revenue
- PBT $18,413,820.00
- TYRA N/A
- Revenue This Year
- PBT N/A
- TYRA N/A
- Revenue Next Year
- PBT N/A
- TYRA N/A
- P/E Ratio
- PBT $48.67
- TYRA N/A
- Revenue Growth
- PBT N/A
- TYRA N/A
- 52 Week Low
- PBT $8.01
- TYRA $6.42
- 52 Week High
- PBT $19.52
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- PBT 57.23
- TYRA 54.47
- Support Level
- PBT $16.75
- TYRA $14.28
- Resistance Level
- PBT $18.00
- TYRA $15.49
- Average True Range (ATR)
- PBT 0.69
- TYRA 0.73
- MACD
- PBT -0.00
- TYRA -0.05
- Stochastic Oscillator
- PBT 93.37
- TYRA 43.89
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.